Ignite Creation Date:
2024-05-06 @ 7:00 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05869669
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-04
First Post:
2023-04-12
Brief Title:
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Sponsor:
EIP Pharma Inc
Organization:
EIP Pharma Inc
Study Overview
Official Title:
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether neflamapimod can improve learning skills problem solving skills and memory loss in people diagnosed with DLB More specifically improvement in verbal learning memory and attention as well as cognitive and functional performance will be measured
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01AG080536 | NIH | None | None |
| 2023-504373-20 | EUDRACT_NUMBER | None | httpsreporternihgovquickSearchR01AG080536 |